AIM: To report a retrospective analysis of preliminary results of 36 patients who received sirolimus (SRL, Rapamune, rapamycin) in a consecutive cohort of 248 liver allograft recipients. METHODS: Thirty-six liver transplant patients with hepatocellular carcinoma (HCC) who were switched to SRL-based immunosuppression therapy from tacrolimus were enrolled in this study. The patients who were diagnosed as advanced HCC before orthotopic liver transplantation (OLT) were divided into group A (n = 11), those who were found to have HCC recurrence and/or metastasis after OLT were assigned to group B (n = 18), and those who developed renal insufficiency caused by calcineurin inhibitor (CNI) were assigned to group C (n = 7) after OLT. RESULTS: The patients were followed up for a median of 10.4 mo (range, 3.8-19.1 mo) after conversion to SRL therapy and 12.3 mo (range, 5.1-34.4 mo) after OLT. Three patients developed mild acute cellular rejection 2 wk after initiating SRL therapy, which was fully reversed after prednisolone pulse therapy. In group A, only 1 patient was found to have HCC recurrence and metastasis 12 mo after OLT. In group B, 66.7% (12/18) patients (2 with progressive tumor, 7 with stable tumor and 3 without tumor) were still alive due to conversing to SRL and/or resection for HCC recurrence at the end of a median follow-up of 6.8 mo post conversion and 10.7 mo posttransplant. In group C, no HCC recurrence was demonstrated in 7 patients, and renal function became normal after SRL therapy. Thrombocytopenia (n = 2), anemia (n = 8), and oral aphthous ulcers (n = 7) found in our cohort were easily manageable. CONCLUSION: The conversion to SRL-based immunosuppression may inhibit the recurrence and metastasis of HCC and improve CNI-induced renal insufficiency in OLT patients with HCC.
AIM: To report a retrospective analysis of preliminary results of 36 patients who received sirolimus (SRL, Rapamune, rapamycin) in a consecutive cohort of 248 liver allograft recipients. METHODS: Thirty-six liver transplant patients with hepatocellular carcinoma (HCC) who were switched to SRL-based immunosuppression therapy from tacrolimus were enrolled in this study. The patients who were diagnosed as advanced HCC before orthotopic liver transplantation (OLT) were divided into group A (n = 11), those who were found to have HCC recurrence and/or metastasis after OLT were assigned to group B (n = 18), and those who developed renal insufficiency caused by calcineurin inhibitor (CNI) were assigned to group C (n = 7) after OLT. RESULTS: The patients were followed up for a median of 10.4 mo (range, 3.8-19.1 mo) after conversion to SRL therapy and 12.3 mo (range, 5.1-34.4 mo) after OLT. Three patients developed mild acute cellular rejection 2 wk after initiating SRL therapy, which was fully reversed after prednisolone pulse therapy. In group A, only 1 patient was found to have HCC recurrence and metastasis 12 mo after OLT. In group B, 66.7% (12/18) patients (2 with progressive tumor, 7 with stable tumor and 3 without tumor) were still alive due to conversing to SRL and/or resection for HCC recurrence at the end of a median follow-up of 6.8 mo post conversion and 10.7 mo posttransplant. In group C, no HCC recurrence was demonstrated in 7 patients, and renal function became normal after SRL therapy. Thrombocytopenia (n = 2), anemia (n = 8), and oral aphthous ulcers (n = 7) found in our cohort were easily manageable. CONCLUSION: The conversion to SRL-based immunosuppression may inhibit the recurrence and metastasis of HCC and improve CNI-induced renal insufficiency in OLT patients with HCC.
Authors: V C McAlister; K M Peltekian; D A Malatjalian; S Colohan; S MacDonald; H Bitter-Suermann; A S MacDonald Journal: Liver Transpl Date: 2001-08 Impact factor: 5.799
Authors: C J Watson; P J Friend; N V Jamieson; T W Frick; G Alexander; A E Gimson; R Calne Journal: Transplantation Date: 1999-02-27 Impact factor: 4.939
Authors: M Majewski; M Korecka; P Kossev; S Li; J Goldman; J Moore; L E Silberstein; P C Nowell; W Schuler; L M Shaw; M A Wasik Journal: Proc Natl Acad Sci U S A Date: 2000-04-11 Impact factor: 11.205
Authors: M Hojo; T Morimoto; M Maluccio; T Asano; K Morimoto; M Lagman; T Shimbo; M Suthanthiran Journal: Nature Date: 1999-02-11 Impact factor: 49.962
Authors: Norman M Kneteman; José Oberholzer; Mohammed Al Saghier; Glenda A Meeberg; Maurice Blitz; Mang M Ma; Winnie W S Wong; Klaus Gutfreund; Andrew L Mason; Larry D Jewell; A M James Shapiro; Vincent G Bain; David L Bigam Journal: Liver Transpl Date: 2004-10 Impact factor: 5.799
Authors: Celina Ang; Ali K Abu-Alfa; Khalid Abdullah; Maeve Lowery; Hassan Sibai; Hassan El Farran; Sally Tamraz; Ashwaq Al Olayan; Ali Shamseddine; Mohamed Naghy; Walid Faraj; Eileen M O'Reilly; Ghassan K Abou-Alfa Journal: Gastrointest Cancer Res Date: 2011-09
Authors: Edward K Geissler; Andreas A Schnitzbauer; Carl Zülke; Philipp E Lamby; Andrea Proneth; Christophe Duvoux; Patrizia Burra; Karl-Walter Jauch; Markus Rentsch; Tom M Ganten; Jan Schmidt; Utz Settmacher; Michael Heise; Giorgio Rossi; Umberto Cillo; Norman Kneteman; René Adam; Bart van Hoek; Philippe Bachellier; Philippe Wolf; Lionel Rostaing; Wolf O Bechstein; Magnus Rizell; James Powell; Ernest Hidalgo; Jean Gugenheim; Heiner Wolters; Jens Brockmann; André Roy; Ingrid Mutzbauer; Angela Schlitt; Susanne Beckebaum; Christian Graeb; Silvio Nadalin; Umberto Valente; Victor Sánchez Turrión; Neville Jamieson; Tim Scholz; Michele Colledan; Fred Fändrich; Thomas Becker; Gunnar Söderdahl; Olivier Chazouillères; Heikki Mäkisalo; Georges-Philippe Pageaux; Rudolf Steininger; Thomas Soliman; Koert P de Jong; Jacques Pirenne; Raimund Margreiter; Johann Pratschke; Antonio D Pinna; Johann Hauss; Stefan Schreiber; Simone Strasser; Jürgen Klempnauer; Roberto I Troisi; Sherrie Bhoori; Jan Lerut; Itxarone Bilbao; Christian G Klein; Alfred Königsrainer; Darius F Mirza; Gerd Otto; Vincenzo Mazzaferro; Peter Neuhaus; Hans J Schlitt Journal: Transplantation Date: 2016-01 Impact factor: 4.939